A study of finerenone for heart failure patients who can't take standard MRA drugs
Treatments studied
Part of Heart & circulation clinical trials.
This study tests whether finerenone, a new type of drug, can help people with heart failure who cannot take standard steroid-based MRAs (a kind of heart medication) because of side effects or other reasons. It aims to see if it improves symptoms and is safe for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have symptomatic heart failure with reduced pumping function (HFrEF).
- You cannot have taken or tolerated a steroid-based MRA drug like spironolactone or eplerenone in the past.
- Your kidney function must be reasonably good (eGFR 25 or higher).
- You cannot have very high potassium levels (over 5.0 mmol/L).
- You must not have had a heart attack, heart surgery, or certain heart procedures in the last 30 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medication called finerenone to see if it helps people hospitalized for heart failure live longer and have fewer heart-related problems. It may be an option for those with a certain type of heart failure where the heart's pumping strength is mildly reduced or normal.
This trial tests a new medicine called finerenone to see if it can reduce heart scarring and improve heart function in people with a certain type of heart failure (preserved ejection fraction). If you qualify, you may help researchers learn if this treatment can help you feel better and stay out of the hospital.
This trial tests whether finerenone can improve heart muscle thickening in patients with certain heart or kidney risk factors. It may help reduce heart strain and improve heart function.
This trial tests a medication called Finerenone to see if it can improve heart structure and function in people with both diabetic kidney disease and heart failure. If you have type 2 diabetes, kidney problems, and heart failure with preserved pumping function, this study may explore a new treatment option for you.
This study compares two medicines, spironolactone and finerenone, to see which one manages potassium levels better in people with heart failure, type 2 diabetes, and kidney disease. Participants have high potassium levels, and the trial aims to find a safer way to manage this.
This study tests whether finerenone, a medication that may help the heart work better, can improve electrical stability in people with a certain type of heart failure (HFpEF). It aims to reduce irregular heart rhythms and improve overall heart health.
Hear when a new Heart failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.